QS Investors’s Revance Therapeutics, Inc. RVNC Stock Holding History

QS Investors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-9,567	Closed	-$241K	–	1266
2020 Q3	$241K	Sell	9,567 -47,522	-83%	-$1.25M	﹤0.01%	1006
2020 Q2	$1.4M	Sell	57,089 -200	-0.3%	-$3.95K	0.02%	625
2020 Q1	$848K	Sell	57,289 -293	-0.5%	-$6.06K	0.01%	710
2019 Q4	$922K	Sell	57,582 -4,072	-7%	-$63.2K	0.01%	798
2019 Q3	$802K	Sell	61,654 -71	-0.1%	-$869	0.01%	830
2019 Q2	$801K	Sell	61,725 -1,436	-2%	-$18.1K	0.01%	862
2019 Q1	$996K	Hold	63,161	–	–	0.01%	813
2018 Q4	$1.27M	Hold	63,161	–	–	0.02%	704
2018 Q3	$1.57M	Hold	63,161	–	–	0.02%	687
2018 Q2	$1.73M	Buy	63,161 +5	+0%	+$150	0.02%	639
2018 Q1	$1.95M	Sell	63,156 -5,303	-8%	-$171K	0.02%	592
2017 Q4	$2.45M	Sell	68,459 -3,407	-5%	-$97.8K	0.02%	537
2017 Q3	$1.98M	Buy	71,866 +12,607	+21%	+$306K	0.02%	611
2017 Q2	$1.56M	Buy	+59,259	New	+$1.32M	0.01%	652
2016 Q1	–	Sell	-10,800	Closed	-$369K	–	2078
2015 Q4	$369K	Buy	+10,800	New	+$374K	﹤0.01%	959

Other funds holding RVNC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

QS Investors's RVNC Position: Q4 2020 in Review

QS Investors sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2020, closing a stake of 9,567 shares — an estimated $241K sold.

QS Investors first reported a position in RVNC in Q4 2015 and held it in 15 quarters. The position peaked at $2.45M in Q4 2017. 151 funds tracked by Wall St. Rank hold RVNC as of Q4 2020.

QS Investors reported no remaining Revance Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
QS Investors sold 9,567 Revance Therapeutics, Inc. shares in Q4 2020, an estimated $241K.
QS Investors first reported a position in Revance Therapeutics, Inc. in Q4 2015 and held it in 15 quarters.
QS Investors's Revance Therapeutics, Inc. position peaked at $2.45M in Q4 2017.
151 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2020.

Based on QS Investors's 13F filing for Q4 2020, filed 10 Feb 2021.